A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Investigator: Juan Toledo Atucha, MD

Study Coordinator: Maushami Gurung

Status: Enrolling

ClinicalTrials.gov Number: NCT04437511

Phone: 346.238.1565

Protocol Number: PRO00025839

Description

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials